Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 11/20 | 0.52 |
| ▸ | PRKDC | P78527 | 2/20 | 0.52 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | LDHB | P07195 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460173 | 1.00 | ATR (0.52) | ATRPRKDCSENP1TP53AURKA | |
| SCHEMBL3461024 | 0.93 | ATR (0.57) | ATRPRKDCLDHALDHB | |
| SCHEMBL3461031 | 0.93 | ATR (0.57) | ATRPRKDCLDHALDHB | |
| SCHEMBL3461249 | 0.91 | ATR (0.52) | ATRPRKDCLDHALDHB | |
| SCHEMBL3461245 | 0.91 | ATR (0.52) | ATRPRKDCLDHALDHB | |
| SCHEMBL3462343 | 0.91 | ATR (0.53) | ATRPRKDCLDHALDHB | |
| SCHEMBL3462344 | 0.91 | ATR (0.53) | ATRPRKDCLDHALDHB | |
| SCHEMBL3460057 | 0.91 | HTR2C (0.51) | ATRPRKDCLDHALDHB | |
| SCHEMBL3460060 | 0.91 | HTR2C (0.51) | ATRPRKDCLDHALDHB | |
| SCHEMBL3462040 | 0.90 | ATR (0.51) | ATRPRKDCLDHALDHBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | claimed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | ATR 556/4885PRKDC 124/4885SENP1 2571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.